Table 1.

Baseline characteristics, follow-up, treatment, and outcomes of 126 patients with not otherwise specified FSGS and 61 patients with collapsing FSGS

CharacteristicsnNOSnCollapsingP ValuenAll
Onset
 Age, yr12637 (20–57)6133 (22–43)0.2318735 (20–54)
 Women12656 (44.4)6140 (65.6)<0.0118796 (51.3)
 Black race12058 (48.3)5848 (82.8)<0.001178106 (59.6)
 Hypertension10455 (52.9)4624 (52.2)>0.9915079 (52.7)
 Serum creatinine, mg/dl1231.2 (0.9–1.8)591.5 (1.0–2.8)0.0021821.4 (0.9–2.1)
 eGFR by MDRD equation, ml/min per 1.73 m212260 (42–92)5648 (26–73)0.0117855 (36–88)
 Up/c, g/g676.6 (2.7–10.1)268.9 (6.4–15.5)0.02937.6 (3.5–11.2)
 24-h Proteinuria, g/d684.4 (2.3–8.1)4112.2 (5.6–14.8)<0.0011095.6 (2.9–12.6)
 Serum albumin, g/dl1042.9 (1.8–3.7)542.4 (1.9–3.0)0.121582.6 (1.8–3.7)
Follow-up
 Duration of follow-up, mo12673 (24–148)6161 (17–117)0.1918769 (22–136)
Treatment
 RAAS inhibition125116 (92.1)5642 (75.0)0.002181158 (87.3)
 Exposure to glucocorticoids alone12535 (28.0)5617 (30.4)0.8618152 (28.7)
 Time to glucocorticoids therapy, mo340.4 (0–0.9)170.1 (0.0–0.5)0.28510.3 (0.0–0.9)
 Length glucocorticoid therapy, mo332.5 (1.9–6.2)173.9 (1.4–6.7)0.73502.7 (1.6–6.7)
 Exposure to CNIs with or without glucocorticoids12546 (36.8)5618 (32.1)0.7318164 (35.4)
 Time to CNI therapy,a mo460.5 (0.03–2.4)180.9 (0.4–1.9)0.40640.6 (0.1–2.0)
 Length of CNI therapy,a mo4511.5 (2.9–31.7)1818.2 (6.1–26.8)0.256313.5 (4.1–31.7)
Outcomes
 Complete or partial remission11472 (63.2)3523 (65.7)0.8414995 (63.8)
 ESRDb12633 (26.2)6129 (47.5)<0.0118762 (33.2)
  • Continuous variables are expressed as medians (interquartile ranges). Categorical variables are expressed as n (%). NOS, not otherwise specified; MDRD, Modification of Diet in Renal Disease; Up/c, urinary protein-to-creatinine ratio; RAAS, renin-angiotensin-aldosterone system; CNI, calcineurin inhibitor.

  • a With or without glucocorticoids.

  • b At last follow-up.